RE:RE:RE:RE:RE:Thoughts on pan can dealThanks to Probo for this very encouraging comment.
It is important to learn that ONCY will have to pay its share of the costs of the trial. However, what its share entails is an important question.
I agree that the selection of the CI to be included in that trial is a fundamental piece of puzzle for ONCY. If is it Roche, one could expect they become our partner leading to a buyout.
Another poster outlined how ONCY could have a trajectory like TRIL as their share price went up, they had an equity raise in which Pfizer participlated leading to a $2.3 bil buyout.
We have a lot more to offer than TRIL, with two and potentially three ph 3 indications if we include CRC, as well as CAR-T and the array of other indications.